Kommentar

• Literatur

• 1 Müller N, Lehmann T, Gerste B. et al. Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health insurance data from Germany. Diabet Med 2017; 34: 1212-1218 . doi:10.1111/dme.13397
• 2 Forst T, Hanefeld M, Jacob S. et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 2013; 10: 302-314
• 3 Hemmingsen B, Schroll JB, Lund SS. et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 4: CD009008 . doi:10.1002/14651858.CD009008.pub2
• 4 Mehnert H. Diabetes mellitus: Gedanken zur Therapie mit Medikamenten (außer Insulin). Diabetes, Stoffwechsel und Herz 2018; 25: 94-95
• 5 Khunti K, Chatterjee S, Gerstein HC. et al. Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes Endocrinol 2018; pii: S2213-8587(18)30025-1 . doi:10.1016/S2213-8587(18)30025-1. [Epub ahead of print]
• 6 Palmer SC, Mavridis D, Nicolucci A. et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA 316: 313-324 . doi:10.1001/jama.2016.9400